严重创伤患者中血栓弹力测量引导的止血复苏:一项倾向性评分匹配研究
该回顾性研究纳入两个创伤中心2012至2019年间收治的、入院24小时内至少输注1单位红细胞的624例创伤患者(传统凝血检测组380例,黏弹性止血检测组244例),经倾向性评分匹配后每组各215例。主要终点为伤后24小时存活且未发生大量输血的比例,黏弹性止血检测组为75%(162例),显著高于传统凝血检测组的52%(112例,p<0.01);黏弹性止血检测组接受大量输血的患者更少(15% vs 42%,p<0.01)。但24小时死亡率(比值比0.94,95%CI 0.59-1.51)和28天生存率(比值比0.87,95%CI 0.58-1.29)均无显著差异。黏弹性止血检测组血制品和凝血因子的总体费用显著降低(中位数2357欧元 vs 4092欧元,p<0.001)。
要点
- 经倾向性评分匹配后,黏弹性止血检测组24小时存活且无大量输血的患者比例为75%(162例),高于传统凝血检测组的52%(112例,p<0.01)。
- 黏弹性止血检测组接受大量输血的患者比例为15%(32例),低于传统凝血检测组的42%(91例,p<0.01)。
- 两组24小时死亡率无显著差异(比值比0.94,95%CI 0.59-1.51),28天生存率亦无显著差异(比值比0.87,95%CI 0.58-1.29)。
- 黏弹性止血检测组血制品和凝血因子的总体费用中位数为2357欧元(四分位距1108-5020),低于传统凝血检测组的4092欧元(四分位距2510-5916,p<0.001)。
适用人群与场景
- 两个创伤中心2012年至2019年收治的严重创伤患者,纳入标准为入院后24小时内至少输注1单位红细胞。
研究设计与关键结果
- 研究类型:回顾性研究,数据来自两个登记处,比较基于黏弹性止血检测(VHA)的算法与基于传统凝血检测(CCT)的算法管理创伤性凝血病(TIC)的两个队列。
- 样本量:2012年至2019年两个创伤中心共收治7250例患者,其中624例纳入研究(CCT组380例,VHA组244例);经倾向性评分匹配后每组各215例,匹配后两组人口学、生命体征、损伤严重度或实验室分析均无显著差异。
- 倾向性评分纳入变量:性别、年龄、钝性伤 vs 穿透伤、收缩压、GCS、ISS和头部AIS、入院乳酸和凝血酶原时间比值(PTratio)、氨甲环酸给药。
- 主要终点:伤后24小时存活且无大量输血(MT)的患者比例,VHA组162例(75%)vs CCT组112例(52%),p<0.01。
- 次要终点:VHA组接受大量输血的患者32例(15%)vs CCT组91例(42%),p<0.01;24小时死亡率比值比0.94(95%CI 0.59-1.51),无显著差异;28天生存率比值比0.87(95%CI 0.58-1.29),无显著差异。
- 费用:血制品和凝血因子总体费用中位数(四分位距)VHA组2357欧元(1108-5020)vs CCT组4092欧元(2510-5916),p<0.001。
证据类型、等级与局限
- 证据类型:回顾性研究,数据来自两个登记处。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在严重创伤患者中,基于VHA的止血复苏策略与24小时存活且无大量输血比例提高、大量输血减少及血制品费用降低相关,但未转化为死亡率改善。
- 原文结论指出,基于VHA的策略与更多患者24小时存活且无大量输血相关,同时显著减少血制品使用及相关费用,但未改善死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To accelerate the diagnosis and treatment of trauma-induced coagulopathy (TIC), viscoelastic haemostatic assays (VHA) are increasingly used worldwide, although their value is still debated, with a recent randomised trial showing no improvement in outcome. The objective of this retrospective study was to compare 2 cohorts of injured patients in which TIC was managed with either a VHA-based algorithm or a conventional coagulation test (CCT)-based algorithm.
METHODS: Data were retrieved from 2 registries and patients were included in the study if they received at least 1 unit of red blood cell in the first 24 h after admission. A propensity score, including sex, age, blunt vs. penetrating, systolic blood pressure, GCS, ISS and head AIS, admission lactate and PTratio, tranexamic acid administration, was then constructed. Primary outcome was the proportion of subjects who were alive and free of massive transfusion (MT) at 24 h after injury. We also compared the cost for blood products and coagulation factors.
RESULTS: From 2012 to 2019, 7250 patients were admitted in the 2 trauma centres, and among these 624 were included in the study (CCT group: 380; VHA group: 244). After propensity score matching, 215 patients remained in each study group without any significant difference in demographics, vital signs, injury severity, or laboratory analysis. At 24 h, more patients were alive and free of MT in the VHA group (162 patients, 75%) as compared to the CCT group (112 patients, 52%; p < 0.01) and fewer patients received MT (32 patients, 15% vs. 91 patients, 42%, p < 0.01). However, no significant difference was observed for mortality at 24 h (odds ratio 0.94, 95% CI 0.59-1.51) or survival at day 28 (odds ratio 0.87, 95% CI 0.58-1.29). Overall cost of blood products and coagulation factors was dramatically reduced in the VHA group as compared to the CCT group (median [interquartile range]: 2357 euros [1108-5020] vs. 4092 euros [2510-5916], p < 0.001).
CONCLUSIONS: A VHA-based strategy was associated with an increase of the number of patients alive and free of MT at 24 h together with an important reduction of blood product use and associated costs. However, that did not translate into an improvement in mortality.
参考来源
- David JS, James A, Orion M, et al. Thromboelastometry-guided haemostatic resuscitation in severely injured patients: a propensity score-matched study. Crit Care. 2023. PMID: 37055832. doi:10.1186/s13054-023-04421-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。